An­tios re­port­ed­ly shut down; Clene's long-term ALS da­ta; Keytru­da, Lenvi­ma's lung can­cer fail­ures

Plus, Val­ne­va signs US con­tract for Ix­i­aro, and Pierre Fab­re inks a can­cer deal with Ver­nalis.

He­pati­tis B start­up An­tios Ther­a­peu­tics shuts down — re­port

An FDA hold tanked An­tios Ther­a­peu­tics, a he­pati­tis B biotech that had raised about $200 mil­lion be­fore shut­ting down ear­li­er this year, per Fierce Biotech. The FDA had placed a hold on An­tios’ Phase IIa tri­al in May 2022 af­ter a pa­tient in a triple com­bi­na­tion por­tion of the study had hy­poten­sion and brady­car­dia. As­sem­bly Bio­sciences quick­ly axed its clin­i­cal tri­al col­lab­o­ra­tion agree­ment with An­tios. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER